CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Terazosin

特拉唑嗪 杂质对照品Terazosin Impurities

EP28 个杂质条目28 impurity entries

本页汇总 特拉唑嗪 的 28 个杂质对照品条目,其中药典杂质标注了 EP/USP 编号。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 28 impurity reference standards of Terazosin with EP/USP numbering where applicable. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 特拉唑嗪(Terazosin)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesStability-Indicating RP-HPLC Method for the Simultaneous Determination of Prazosin, Terazosin, and Doxazosin in Pharmaceutical Formulations
    Scientia pharmaceutica · 2012 · Shrivastava A, Gupta VB  ·  PMID 23008810  ·  DOI
  2. 杂质研究Impurity studiesUpdating the European Pharmacopoeia impurity profiling method for terazosin and suggesting alternative columns
    Journal of pharmaceutical and biomedical analysis · 2020 · Enesei D et al.  ·  PMID 32460215  ·  DOI
  3. 杂质研究Impurity studiesValidated specific HPLC methods for determination of prazosin, terazosin and doxazosin in the presence of degradation products formed under ICH-recommended stress conditions
    Journal of pharmaceutical and biomedical analysis · 2004 · Bakshi M et al.  ·  PMID 14738915  ·  DOI
  4. 分析方法Analytical MethodsA QbD-based method for the simultaneous determination of tadalafil, terazosin, and tamsulosin using organic-solvent free mixed-micellar HPLC: a sustainable green approach
    BMC chemistry · 2026 · Alrashdi YBA et al.  ·  PMID 42387558  ·  DOI
  5. 分析方法Analytical MethodsHighly Sensitive Fluorescence Methods for the Determination of Alfuzosin, Doxazosin, Terazosin and Prazosin in Pharmaceutical Formulations, Plasma and Urine
    Analytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2016 · Guo X et al.  ·  PMID 27396658  ·  DOI

特拉唑嗪 —— 原料药与杂质对照品Terazosin — drug substance & impurities

共 28 个条目(含原料药本体)28 items incl. the drug substance
Terazosin Impurity 1(Terazosin EP Impurity A) structure
EPA
特拉唑嗪杂质1(特拉唑嗪EP杂质A)Terazosin Impurity 1(Terazosin EP Impurity A)
Terazosin Impurity 1(Terazosin EP Impurity A)
CAS No.23680-84-4
Chemical FormulaC10H10ClN3O2
Purity>95%询价On request
10mg25mg50mg100mg
Terazosin Impurity 3(Terazosin EP Impurity B) structure
EPB
特拉唑嗪杂质3(特拉唑嗪EP杂质B)Terazosin Impurity 3(Terazosin EP Impurity B)
Terazosin Impurity 3(Terazosin EP Impurity B)
CAS No.1177261-73-2
Chemical FormulaC19H24N4O5
Purity>95%询价On request
10mg25mg50mg100mg
Terazosin Impurity 2(Terazosin EP Impurity C) structure
EPC
特拉唑嗪杂质2(特拉唑嗪EP杂质C)Terazosin Impurity 2(Terazosin EP Impurity C)
Terazosin Impurity 2(Terazosin EP Impurity C)
CAS No.60547-97-9
Chemical FormulaC14H19N5O2
Purity>95%询价On request
10mg25mg50mg100mg
Terazosin Impurity 2 Dihydrochloride(Terazosin EP Impurity C Dihydrochloride) structure
EPC
特拉唑嗪杂质2 双盐酸盐(特拉唑嗪EP杂质C 双盐酸盐)Terazosin Impurity 2 Dihydrochloride(Terazosin EP Impurity C Dihydrochloride)
Terazosin Impurity 2 Dihydrochloride(Terazosin EP Impurity C Dihydrochloride)
CAS No.60548-08-5
Chemical FormulaC14H19N5O2·2HCl
Purity>95%询价On request
10mg25mg50mg100mg
Terazosin Impurity 4(Terazosin EP Impurity D) structure
EPD
特拉唑嗪杂质4(特拉唑嗪EP杂质D)Terazosin Impurity 4(Terazosin EP Impurity D)
Terazosin Impurity 4(Terazosin EP Impurity D)
CAS No.102714-74-9
Chemical FormulaC15H19N5O3
Purity>95%询价On request
10mg25mg50mg100mg
Terazosin Impurity 5 (Terazosin EP Impurity E) structure
EPE
特拉唑嗪杂质5 (特拉唑嗪EP杂质E)Terazosin Impurity 5 (Terazosin EP Impurity E)
Terazosin Impurity 5 (Terazosin EP Impurity E)
CAS No.102839-00-9
Chemical FormulaC24H28N8O4
Purity>95%询价On request
10mg25mg50mg100mg
Terazosin Impurity 6(Terazosin EP Impurity F) structure
EPF
特拉唑嗪杂质6(特拉唑嗪EP杂质F)Terazosin Impurity 6(Terazosin EP Impurity F)
Terazosin Impurity 6(Terazosin EP Impurity F)
CAS No.2448263-83-8
Chemical FormulaC19H27N5O4·HCl
Purity>95%询价On request
10mg25mg50mg100mg
Terazosin Impurity 7(Terazosin EP Impurity G) structure
EPG
特拉唑嗪杂质7(特拉唑嗪EP杂质G)Terazosin Impurity 7(Terazosin EP Impurity G)
Terazosin Impurity 7(Terazosin EP Impurity G)
CAS No.105356-89-6
Chemical FormulaC18H23N5O4
Purity>95%询价On request
10mg25mg50mg100mg
Terazosin Impurity 8(Terazosin EP Impurity H) structure
EPH
特拉唑嗪杂质8(特拉唑嗪EP杂质H)Terazosin Impurity 8(Terazosin EP Impurity H)
Terazosin Impurity 8(Terazosin EP Impurity H)
CAS No.111013-28-6
Chemical FormulaC18H24ClN5O4
Purity>95%询价On request
10mg25mg50mg100mg
Terazosin Impurity 9 (Terazosin EP Impurity I) structure
EPI
特拉唑嗪杂质9(特拉唑嗪EP杂质I)Terazosin Impurity 9 (Terazosin EP Impurity I)
Terazosin Impurity 9 (Terazosin EP Impurity I)
CAS No.1177261-85-6
Chemical FormulaC20H27N5O4
Purity>95%询价On request
10mg25mg50mg100mg
Terazosin Impurity 10(Terazosin EP Impurity J) structure
EPJ
特拉唑嗪杂质10(特拉唑嗪EP杂质J)Terazosin Impurity 10(Terazosin EP Impurity J)
Terazosin Impurity 10(Terazosin EP Impurity J)
CAS No.152551-75-2
Chemical FormulaC19H27N5O4
Purity>95%询价On request
10mg25mg50mg100mg
Terazosin Impurity 11(Terazosin EP Impurity K) structure
EPK
特拉唑嗪杂质11(特拉唑嗪EP杂质K)Terazosin Impurity 11(Terazosin EP Impurity K)
Terazosin Impurity 11(Terazosin EP Impurity K)
CAS No.19216-56-9
Chemical FormulaC19H21N5O4
Purity>95%询价On request
10mg25mg50mg100mg
Terazosin Impurity 12 (Terazosin EP Impurity L) structure
EPL
特拉唑嗪杂质12 (特拉唑嗪EP杂质L)Terazosin Impurity 12 (Terazosin EP Impurity L)
Terazosin Impurity 12 (Terazosin EP Impurity L)
CAS No.40172-95-0
Chemical FormulaC9H12N2O2
Purity>95%询价On request
10mg25mg50mg100mg
Terazosin Impurity 12 Hydrochloride (Terazosin EP Impurity L Hydrochloride) structure
EPL
特拉唑嗪杂质12 盐酸盐 (特拉唑嗪EP杂质L 盐酸盐)Terazosin Impurity 12 Hydrochloride (Terazosin EP Impurity L Hydrochloride)
Terazosin Impurity 12 Hydrochloride (Terazosin EP Impurity L Hydrochloride)
CAS No.60548-09-6
Chemical FormulaC9H12N2O2·HCl
Purity>95%询价On request
10mg25mg50mg100mg
Terazosin Impurity 13(Terazosin EP Impurity M) structure
EPM
特拉唑嗪杂质13(特拉唑嗪EP杂质M)Terazosin Impurity 13(Terazosin EP Impurity M)
Terazosin Impurity 13(Terazosin EP Impurity M)
CAS No.31350-27-3
Chemical FormulaC14H14N2O4
Purity>95%询价On request
10mg25mg50mg100mg
Terazosin Impurity 27 (N-Nitroso Terazosin EP Impurity N) structure
EPN
特拉唑嗪杂质27 (N-亚硝基特拉唑嗪EP杂质N)Terazosin Impurity 27 (N-Nitroso Terazosin EP Impurity N)
Terazosin Impurity 27 (N-Nitroso Terazosin EP Impurity N)
CAS No.2470438-57-2
Chemical FormulaC9H15N3O3
Purity>95%询价On request
10mg25mg50mg100mg
Terazosin Impurity 14 (Terazosin EP Impurity N) structure
EPN
特拉唑嗪杂质14 (特拉唑嗪EP杂质N)Terazosin Impurity 14 (Terazosin EP Impurity N)
Terazosin Impurity 14 (Terazosin EP Impurity N)
CAS No.63074-07-7
Chemical FormulaC9H16N2O2
Purity>95%询价On request
10mg25mg50mg100mg
Terazosin Impurity 14 Hydrobromide (Terazosin EP Impurity N Hydrobromide) structure
EPN
特拉唑嗪杂质14 氢溴酸盐 (特拉唑嗪EP杂质N 氢溴酸盐)Terazosin Impurity 14 Hydrobromide (Terazosin EP Impurity N Hydrobromide)
Terazosin Impurity 14 Hydrobromide (Terazosin EP Impurity N Hydrobromide)
CAS No.63590-62-5
Chemical FormulaC9H16N2O2·HBr
Purity>95%询价On request
10mg25mg50mg100mg
Terazosin Impurity 15(Terazosin EP Impurity O) structure
EPO
特拉唑嗪杂质15(特拉唑嗪EP杂质O)Terazosin Impurity 15(Terazosin EP Impurity O)
Terazosin Impurity 15(Terazosin EP Impurity O)
CAS No.547730-06-3
Chemical FormulaC14H22N2O4
Purity>95%询价On request
10mg25mg50mg100mg
Terazosin Impurity 16 structure
16
特拉唑嗪杂质16Terazosin Impurity 16
Terazosin Impurity 16
CAS No.109351-34-0
Chemical FormulaC19H25N5O4
Purity>95%询价On request
10mg25mg50mg100mg
Terazosin Impurity 17 structure
17
特拉唑嗪杂质17Terazosin Impurity 17
Terazosin Impurity 17
CAS No.1260939-66-9
Chemical FormulaC19H27N5O4
Purity>95%询价On request
10mg25mg50mg100mg
Terazosin Impurity 18 structure
18
特拉唑嗪杂质18Terazosin Impurity 18
Terazosin Impurity 18
CAS No.84050-22-6
Chemical FormulaC15H21ClN4O2
Purity>95%询价On request
10mg25mg50mg100mg
Terazosin Impurity 19 structure
19
特拉唑嗪杂质19Terazosin Impurity 19
Terazosin Impurity 19
CAS No.412334-56-6
Chemical FormulaC9H16N2O2
Purity>95%询价On request
10mg25mg50mg100mg
Terazosin Impurity 21 structure
21
特拉唑嗪杂质21Terazosin Impurity 21
Terazosin Impurity 21
CAS No.16874-33-2
Chemical FormulaC5H8O3
Purity>95%询价On request
10mg25mg50mg100mg
Terazosin Impurity 22 structure
22
特拉唑嗪杂质22Terazosin Impurity 22
Terazosin Impurity 22
CAS No.87392-07-2
Chemical FormulaC5H8O3
Purity>95%询价On request
10mg25mg50mg100mg
Terazosin Impurity 23 structure
23
特拉唑嗪杂质23Terazosin Impurity 23
Terazosin Impurity 23
CAS No.2470437-02-4
Chemical FormulaC19H25N5O4
Purity>95%询价On request
10mg25mg50mg100mg
Terazosin Impurity 24 structure
24
特拉唑嗪杂质24Terazosin Impurity 24
Terazosin Impurity 24
CAS No.1096446-01-3
Chemical FormulaC9H16N2O2
Purity>95%询价On request
10mg25mg50mg100mg
Terazosin Impurity 25 structure
25
特拉唑嗪杂质25Terazosin Impurity 25
Terazosin Impurity 25
CAS No.63590-64-7
Chemical FormulaC19H25N5O4
Purity>95%询价On request
10mg25mg50mg100mg
本品种含亚硝胺类杂质条目。亚硝胺杂质属于 ICH M7 关注的潜在致突变杂质,建议在方法开发中纳入专属性考察。This list includes nitrosamine entries. Nitrosamines are potential mutagenic impurities under ICH M7 and should be covered by a specific method.

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

特拉唑嗪 —— 研究文献与合成路线Terazosin — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 特拉唑嗪 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Terazosin. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. Validated specific HPLC methods for determination of prazosin, terazosin and doxazosin in the presence of degradation products formed under ICH-recommended stress conditions
    Bakshi M, Ojha T, Singh S · Journal of pharmaceutical and biomedical analysis · 2004 · 被引 20cited 20
  2. Updating the European Pharmacopoeia impurity profiling method for terazosin and suggesting alternative columns
    Enesei D, Kapui I, Fekete S, et al. · Journal of pharmaceutical and biomedical analysis · 2020 · 被引 8cited 8
  3. Stability-Indicating RP-HPLC Method for the Simultaneous Determination of Prazosin, Terazosin, and Doxazosin in Pharmaceutical Formulations
    Shrivastava A, Gupta VB · Scientia pharmaceutica · 2012 · 被引 9cited 9
  4. Sensitive determination of terazosin in pharmaceutical formulations and biological samples by ionic-liquid microextraction prior to spectrofluorimetry
    Zeeb M, Sadeghi M · International journal of analytical chemistry · 2012 · 被引 6cited 6

合成与制备工艺专利Synthesis & process patents

  1. Terazosin slowly releasing preparation
    HE YAN · 公开号 CN1927166CN1927166 · 2007
  2. Application of terazosin for preparing medicines for treating postpartum urinary retention
    SHAOFANG SUN, BING SUN, JINGCHUAN ZHANG, YUANYUAN YANG, et al. · 公开号 CN101444512CN101444512 · 2009
  3. Method for preparing terazosin hydrochloride of optical activity
    WAN BAOKUN · 公开号 CN1563001CN1563001 · 2005
  4. Terazosin Hydrochloride drop pill and preparing method thereof
    QIAN JIN, XU JUN, PENGHON · 公开号 CN1528311CN1528311 · 2004
  5. PREPARATION OF TERAZOSIN HYDROCHLORIDE DIHYDRATE
    SCHWARTZ EDUARD, MENDELOVICI MARIOURA, GERSHON NEOMI · 公开号 WO9925715WO9925715 · 1999

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

特拉唑嗪 杂质谱研究要点Terazosin — impurity profiling notes

下面这些是拿到 特拉唑嗪 的 28 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 28 impurity entries for Terazosin, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

本品种含药典编号杂质(EP/USP)。申报时药典已收载的杂质通常需要逐项对照,建议优先备齐药典编号对照品,再补充工艺与降解杂质。This drug substance includes pharmacopoeially designated impurities (EP/USP). Monographed impurities normally need item-by-item comparison during filing, so secure the pharmacopoeial standards first, then fill in process and degradation impurities.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances